Psyence BioMed Announces Exclusive U.S. Ibogaine Licence for Texas Ibogaine Research Corporation
Psyence BioMed's Texas subsidiary TIRC signed a binding term sheet with PsyLabs for an exclusive U.S. license, supply and wholesale distribution arrangement covering PsyLabs' pharmaceutical-grade ibogaine. TIRC will pay up to roughly US$1.3 million in milestone payments plus a low single-digit royalty on net sales, with exclusivity conditional on sourcing all U.S. ibogaine from PsyLabs.
Key figures
- Royalty
- low single-digit percentage royalty on net sales
- Milestone payments usd
- 1300000
- Definitive agreement deadline
- November 30, 2026
AI analysis
Red flags5 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.